9393 results about "Blood sugar" patented technology

A method is provided for calibrating a noninvasive glucose monitor for prospective noninvasive glucose determination. Spectroscopic transflectance readings are measured on the patient's skin using a noninvasive glucose monitor. The patient's blood glucose level is measured with an invasive glucose monitor. The noninvasive and invasive measurements are correlated to form an individual algorithm for each patient. Preferably, the position of the patient's skin with respect to the probe of the noninvasive monitor is spatially adjusted while collecting the transflectance measurements such that multiple readings are taken on the patient's skin. The measurements are preferably taken over a period of time and over a plurality of glucose levels in the patient.

Apparatuses and methods for medical monitoring physiological characteristic values such as blood glucose levels for the treatment of diabetes, are presented. The apparatuses and methods provide advanced alarm and reminder functions, as well as advanced data presentation tools to further facilitate convenient and efficient management of various physiological conditions. For example, an alarm repeat delay can be used to prevent redundant alarms for a specified period and an alarm snooze function can be used to prevent alarms generally for a specified period.

The present invention relates to a method for estimating blood glucose levels using a noninvasive optical coherence tomography- (OCT-) based blood glucose monitor. An algorithm correlates OCT-based estimated blood glucose data with actual blood glucose data determined by invasive methods. OCT-based data is fit to the obtained blood glucose measurements to achieve the best correlation. Once the algorithm has generated sets of estimated blood glucose levels, it may refine the number of sets by applying one or more mathematical filters. The OCT-based blood glucose monitor is calibrated using an Intensity Difference plot or the Pearson Product Moment Correlation method.

An analyte sensor and systems for determining analyte levels in a user's body. The analyte sensor and systems are adapted to be used with single dose medication devices and include a communication system to transmit the communications from the analyte sensor to the user to notify the user of an estimated amount of fluid to deliver to the user's body. More particularly, these apparatuses and methods for use are for providing convenient monitoring of blood glucose levels in determining the appropriate amount of insulin to deliver.

A dosage determination supporting apparatus, which is able to precisely determine a dosage in accordance with the health condition of a user, is provided with: a sensor (28) for measuring the blood sugar level obtained from the blood of the user; a memory (48) for storing an operation table showing a correspondence between the blood sugar level and the amount of insulin; a CPU (50) for calculating the amount of insulin corresponding to the blood sugar level, with reference to the operation table stored in the memory (48); a displaying unit (34) for displaying the amount of insulin; and a voice processing unit (52) for performing the voice processing on the amount of insulin and outputting the voice through a speaker (32).

An apparatus and method may provide a system, apparatus and method for monitoring diabetes, including a server to serve data to a cellular communications network; a communications device including a wireless transceiver; a cellular network to enable data to be communicated between the communication device and the server; and a diabetes monitoring device including a wireless transceiver, to enable data to be communicated between the monitoring device and the communication device. The diabetes monitoring device may include sensors for monitoring one or more of for example blood glucose level, physical activity, energy intake and insulin dosage.

A system and method for continuous non-invasive glucose monitoring is disclosed. According to one embodiment of the present invention, the method includes the steps of (1) contacting a remote device to an area of biological membrane having a permeability level, the remote device comprising a sensor and a transmitter; (2) extracting the at least one analyte through and out of the area of biological membrane and into the sensor; (3) generating an electrical signal representative of a level of the at least one analyte; (4) transmitting the electrical signal to a base device; (5) processing the electrical signal to determine the level of the at least one analyte; and (6) displaying the level of the at least one analyte in real time. The system includes a remote device that includes a sensor that generates an electrical signal representative of the concentration of the at least one analyte; and a transmitter that transmits the electrical signal. The system further includes a base device that includes a receiver that receives the electrical signal; a processor that processes the electrical signal; and a display that displays the processed signal in real time.

A method for noninvasively measuring analytes such as blood glucose levels includes using a non-imaging OCT-based system to scan a two-dimensional area of biological tissue and gather data continuously during the scanning. Structures within the tissue where measured-analyte-induced changes to the OCT data dominate over changes induced by other analytes are identified by focusing on highly localized regions of the data curve produced from the OCT scan which correspond to discontinuities in the OCT data curve. The data from these localized regions then can be related to measured analyte levels.

Present invention is a system of blood glucose monitoring and intensive insulin therapy in a ICU for strict maintenance of normoglycemia which reduces intensive care and hospital mortality and morbidity of critically ill adult patients. The findings of present study also reveal factors determining insulin doses needed to maintain normoglycemia as well as the impact of insulin dose versus blood glucose level on the observed outcome benefits have been established. The invention provides a control system that adapts the flow of the insulin infusion based on insulin requirement calculated by blood glucose levels and clinical parameters such as history of diabetes, Body Mass Index, blood glucose level on admission, reason of ICU admission, time in the ICU, type and severity of illness, caloric intake, obesity, drugs affecting insulin sensitivity). This automated insulin monitoring systems significantly reduces the workload and human resource management problems for intensive insulin therapy in patients in the ICU.

Accordingly, the present invention relates to a three-dimensional adhesive device to be attached to the body surface of a mammal comprising a microelectronic sensing system characterized by(a) a three-dimensional adhesive body made of a pressure sensitive adhesive having an upper surface and a bottom surface;(b) a microelectronic system embedded in the body of the pressure sensitive adhesive;(c) one or more cover layer(s) attached to the upper surface; and(d) optionally a release liner releasable attached to the bottom surface of the adhesive device.Suitably the microelectronic system is a microelectronic sensing system capable of sensing physical input such as pressure, vibration, sound, electrical activity (e.g. from muscle activity), tension, blood-flow, moisture, temperature, enzyme activity, bacteria, pH, blood sugar, conductivity, resistance, capacitance, inductance or other chemical, biochemical, biological, mechanical or electrical properties.

Apparatuses and methods for medical monitoring physiological characteristics values such as blood glucose levels for the treatment of diabetes, are presented. The apparatuses and methods provide dynamic glucose monitoring functions that perform predictive analysis to anticipate harmful conditions, such as glucose crash and hyperglycemic incidents for a patient. The dynamic functions can also be used to maximize athletic performance and warn of inadequate nocturnal basal rate. Other aspects include advanced alarm and reminder functions, as well as advanced data presentation tools to further facilitate convenient and efficient management of various physiological conditions.

Apparatuses and methods for medical monitoring physiological characteristics values such as blood glucose levels for the treatment of diabetes, are presented. The apparatuses and methods provide dynamic glucose monitoring functions that perform predictive analysis to anticipate harmful conditions, such as glucose crash and hyperglycemic incidents for a patient. The dynamic functions can also be used to maximize athletic performance and warn of inadequate nocturnal basal rate. Other aspects include advanced alarm and reminder functions, as well as advanced data presentation tools to further facilitate convenient and efficient management of various physiological conditions.

A method of calibrating glucose monitor data includes collecting the glucose monitor data over a period of time at predetermined intervals, obtaining reference glucose values from a reference source that temporally correspond with the glucose monitor data obtained at the predetermined intervals, calculating the calibration characteristics using the reference glucose values and corresponding glucose monitor data to regress the obtained glucose monitor data, and calibrating the obtained glucose monitor data using the calibration characteristics. In additional embodiments, calculation of the calibration characteristics includes linear regression and, in particular embodiments, least squares linear regression. Alternatively, calculation of the calibration characteristics includes non-linear regression. Data integrity may be verified and the data may be filtered. Further, calibration techniques may be modified during a fast rate of change in the patient's blood glucose level to increase sensor accuracy.

A diabetes management system and method used to manage the blood glucose level of a diabetes patient. The system includes at least one portable electronic device and a database system. The portable electronic device allows the patient to input different types of data into the processor to calculate insulin and carbohydrate intake recommendations for the patient. A time / date stamp is individually generated and stored for each type of data inputted by the patient. The diabetes management system also includes a database system which stores (i) activity data associated with the physical activity of the patient, (ii) blood glucose data associated with the blood glucose level of the patient, (iii) meal intake data associated with the food intake of the patient, and (iv) insulin intake data associated with the insulin intake of the patient.

Various methods and apparatuses for measuring a state parameter of an individual using signals based on one or more sensors are disclosed. In one embodiment, a first set of signals is used in a first function to determine how a second set of signals is used in one or more second functions to predict the state parameter. In another embodiment, first and second functions are used where the state parameter or an indicator of the state parameter may be obtained from a relationship between the first function and the second function. The state parameter may, for example, include blood glucose levels, calories consumed or calories burned by the individual. Various methods for making such apparatuses are also disclosed.

A combined peripheral and health monitoring device for use with a computer is disclosed. The device can include a sensor adapted to sense one or more medical parameters such as blood glucose levels, medical circuitry in communication with the sensor for processing the one or more sensed medical parameters, and a communications interface for transmitting and receiving data back and forth between the device and the computer.

Systems and methods provide intrabody communication using acoustic telemetry. The system includes a first or control implant including a first acoustic transducer, and a second implant including a switch and a second acoustic transducer coupled to the switch. The second acoustic transducer receives acoustic signals from the first acoustic transducer for closing the switch to activate the second implant. The second implant may include a sensor for measuring a physiological parameter that is transmitted using acoustic signals including the physiological data to the first implant. For example, the second implant may measure pressure in the patient's heart that may be used by the first implant to control a pacemaker. Alternatively, the second implant may blood sugar concentration that may be used by the first implant to control an insulin pump. Alternatively, the first implant may store and transfer the data to an external device for monitoring the patient.

A method and device are provided for self-monitoring a patient's blood glucose condition to determine a long-term effect of the patient's behavior on his blood glucose level. A sequence of measurements of the blood glucose level is applied during a day, the sequential measurements are repeated during a predetermined time period from several days to several weeks, and measured data are collected. The measured data is analyzed to determine a distribution of the average glucose values within said predetermined time period, thereby providing a feedback for the patient or an authorized person.

Apparatuses and methods for medical monitoring physiological characteristic values such as blood glucose levels for the treatment of diabetes, are presented. The apparatuses and methods provide advanced alarm and reminder functions, as well as advanced data presentation tools to further facilitate convenient and efficient management of various physiological conditions. For example, an alarm repeat delay can be used to prevent redundant alarms for a specified period and an alarm snooze function can be used to prevent alarms generally for a specified period.

A method for controlling an insulin pump using the Bluetooth protocol. The method comprises allocating IDs to insulin pumps and blood sugar level measuring devices, respectively; checking, in a corresponding insulin pump, whether or not blood sugar level data is inputted from a blood sugar level measuring device having a corresponding ID; cumulating inputted data and judging whether or not abnormality occurs; generating a command to allow the insulin pump to operate as it is, when abnormality did not occur; generating a command to change an insulin injection amount of the insulin pump when abnormality occurred, and then, returning to the third step; and determining a system to be out of order when data is not inputted in the checking step, and generating an alarm so that a qualified person can visit a corresponding patient to have a trouble to be directly addressed.

The method and system for managing a patient's blood glucose level predicts an insulin dosing rate to bring a patient's blood glucose level into a preferred target range within a predetermined time interval. The system includes a processor which actuates a blood glucose computer program to measure and predict the patient's blood glucose level. An input mechanism allows for insertion of a preferred target range of the patient's blood glucose level and further permits input of various patient data parameters. The processor calculates the optimum insulin dosing rate for the patient based upon the type of insulin dosing whether it be intravenous dosing and / or subcutaneous dosing. A display mechanism displays the patient dosing parameters and an alarm mechanism alerts a user when the patient's blood glucose level is outside of the preferred patient blood glucose target range.

This invention relates to methods for processing in vivo skin auto-fluorescence spectra for determining blood glucose levels. The invention also relates to methods of classifying cells or tissue samples or quantifying a component of a cell or tissue using a multivariate classification or quantification model.

Disclosed are methods and apparatuses for determining analyte concentration in a sample such as bodily fluid. Systems and methods disclosed herein can also include a treatment dosing system to infuse or inject a treatment dose (e.g. insulin, dextrose, etc.) and provide glycemic control. The dose of the treatment drug may be based on the patient's calculated sensitivity to treatment dosing, for example. The dose of the treatment drug may be based on the concentration of the analyte or the average value for the concentration of the analyte and / or the rate of change of the value of the concentration of the analyte. Delivery of the treatment drug can be cut off if the determined analyte concentration indicates that continued delivery would be harmful to the patient.

Microvascular complications of diabetes mellitus are closely related to blood glucose levels and fluctuations. The Glycostator statistical package was created to allow patients and health care providers simple access to “glycemic indicators” which permit a “snapshot view” of the effectiveness of the patient's diabetes management program. Glycostator functions provide a simple way of enhancing the information already provided by home blood glucose monitoring devices. To this end, a set of new indices, including one called the Virtual A1c, are computed in a recursive fashion from blood glucose test results to provide a more meaningful day-to-day assessment of glycemic control. All indices can be made available at the meter user interface on request. The displayed indices allow patients to improve glycemic control by identifying problems with blood glucose control and lability that are less easily recognized in traditional blood glucose meter statistical packages. Virtual A1c emulates hemoglobin A1c continuously and provides better day-to-day assessment of long term glycemic control than does the traditional average blood glucose report. The method for computing each of these indices, including the Virtual A1c, allows for their implementation in commercial blood glucose monitors.

A device and method are provided for use with a noninvasive optical measurement system, such as a thermal gradient spectrometer, for improved determination of analyte concentrations within living tissue. In one embodiment, a wearable window is secured to a patient's forearm thereby isolating a measurement site on the patient's skin for determination of blood glucose levels. The wearable window effectively replaces a window of the spectrometer, and thus forms an interface between the patient's skin and a thermal mass window of the spectrometer. When the spectrometer must be temporarily removed from the patient's skin, such as to allow the patient mobility, the wearable window is left secured to the forearm so as to maintain a consistent measurement site on the skin. When the spectrometer is later reattached to the patient, the wearable window will again form an interface between the spectrometer and the same location of skin as before.

The determination of blood glucose in an individual is carried out by projecting illuminating light into an eye of the individual to illuminate the retina with the light having wavelengths that are absorbed by rhodopsin and with the intensity of the light varying in a prescribed temporal manner. The light reflected from the retina is detected to provide a signal corresponding to the intensity of the detected light, and the detected light signal is analyzed to determine the changes in form from that of the illuminating light. For a biased sinusoidal illumination, these changes can be expressed in terms of harmonic content of the detected light. The changes in form of the detected light are related to the ability of rhodopsin to absorb light and regenerate, which in turn is related to the concentration of blood glucose, allowing a determination of the relative concentration of blood glucose. Other photoreactive analytes can similarly be determined by projecting time varying illuminating light into the eye, detecting the light reflected from the retina, and analyzing the detected light signal to determine changes in form of the signal due to changes in absorptivity of a photoreactive analyte.

A system for measuring a glucose level in a blood sample includes a test strip and a meter. The test strip includes a sample chamber or other testing zone, a working electrode, a counter electrode, fill-detect electrodes, and an auto-on conductor. A reagent layer is disposed in the testing zone. The auto-on conductor causes the meter to wake up and perform a test strip sequence when the test strip is inserted in the meter. The meter uses the working and counter electrodes to initially detect the blood sample in the sample chamber and uses the fill-detect electrodes to check that the blood sample has mixed with the reagent layer. The meter applies an assay voltage between the working and counter electrodes and measures the resulting current. The meter calculates the glucose level based on the measured current and calibration data saved in memory from a removable data storage device associated with the test strip.

The present invention provides contact lens with integrated biosensor for the continuous, non-invasive monitoring of physiological glucose by employing biocompatible nanostructure-laden lens materials. These contact lenses can be worn by diabetics who can colorimetrically see changes in their contact lens color or other fluorescence-based properties, giving an indication of tear and blood glucose levels. This invention for the glucose biosensor based on the new disposal contact lens provides a safe, convenient and non-expensive glucose sensing device. The sensing device disclosed herein provides an efficient and noninvasive solution for monitoring blood glucose.